Expert Interview
A second look: Discovering the potential of Axsome's AXS-12 (reboxetine) a selective and potent norepinephrine reuptake inhibitor for the treatment of narcolepsy and cataplexy after the release of its phase 2 data.
Ticker(s): AXSM- Board-certified neurologist and sleep physician and a leading voice in sleep medicine,
- Has written more than 1000 articles over the past decade.
- Was a sleep fellow at Stanford University and lectures extensively.
- Treats approximately 25 patients with narcolepsy and cataplexy
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
